Pasithea Therapeutics (KTTA) Return on Equity (2021 - 2026)

Pasithea Therapeutics' Return on Equity history runs 6 years deep, the most recent figure standing at 0.0% for Q1 2026.

• In Q1 2026, Return on Equity rose 1.0% year-over-year to 0.0%; the TTM figure through Mar 2026 stood at 0.0% (up 1.0% YoY), while the FY2025 annual figure was 0.01%, changed 0.0% from the prior year.
• Return on Equity came in at 0.0% for Q1 2026 at Pasithea Therapeutics, up from 0.01% in the prior quarter.
• In the past five years, Return on Equity ranged from a high of 0.0% in Q3 2022 to a low of 0.01% in Q3 2025.
• A 5-year average of 0.0% and a median of 0.0% in 2024 frame the typical range for Return on Equity.
• Across the five-year window, Return on Equity retreated 1 bps in 2024 and increased 1 bps in 2026, its largest moves.
• Pasithea Therapeutics' Return on Equity stood at 0.0% in 2022, then jumped by 65 bps to 0.0% in 2023, then sank by 4765 bps to 0.01% in 2024, then gained by 29 bps to 0.01% in 2025, then surged by 41 bps to 0.0% in 2026.
• According to Business Quant data, Return on Equity over the past three periods registered 0.0%, 0.01%, and 0.01% for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison